Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1642 Inhibitors

Olr1642 inhibitors represent a chemical class defined by their ability to selectively inhibit the function of the Olr1642 receptor, a member of the olfactory receptor family. Olfactory receptors, primarily known for their role in detecting odor molecules, are G-protein-coupled receptors (GPCRs) widely expressed in the olfactory epithelium. The Olr1642 receptor, like other olfactory receptors, has a highly conserved seven-transmembrane domain structure typical of GPCRs, which allows it to interact with specific ligands. The inhibitors of Olr1642 are typically small organic molecules designed or discovered to bind to this receptor with high specificity, effectively blocking the receptor's ability to engage in its normal ligand-binding processes. This inhibition can result in altered receptor signaling pathways, which are crucial in understanding the receptor's physiological roles beyond olfaction, particularly in non-olfactory tissues where such receptors are increasingly being studied.

The development of Olr1642 inhibitors involves the identification of key structural motifs within these molecules that can interact efficiently with the receptor's active site. These inhibitors are often designed using structure-based drug design (SBDD) approaches, where computational models of the receptor are used to screen and optimize potential inhibitory compounds. Key to the effectiveness of these inhibitors is their ability to achieve selectivity, meaning they should interact with the Olr1642 receptor without affecting other closely related olfactory receptors. Achieving such selectivity often requires a deep understanding of the receptor's binding pocket and the molecular interactions that govern ligand recognition and binding. Research into Olr1642 inhibitors continues to evolve, providing valuable insights into receptor-ligand interactions and the broader implications of GPCR modulation in cellular signaling pathways.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor, potentially disrupts protein degradation pathways.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor, potentially interrupts MAPK/ERK signaling pathways.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Bruton's tyrosine kinase inhibitor, potentially affects B-cell receptor signaling.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

MET, VEGFR2, and RET inhibitor, potentially disrupts cell proliferation and angiogenesis.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, potentially effective against T790M mutation in lung cancer.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, potentially inhibits angiogenesis and oncogenesis.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

JAK1 and JAK2 inhibitor, potentially affects cytokine and growth factor signaling.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$153.00
$938.00
5
(0)

Multi-targeted receptor tyrosine kinase inhibitor, potentially inhibits angiogenesis.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$111.00
$357.00
8
(0)

Immunomodulatory drug, potentially affects TNF-α production and angiogenesis.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, potentially induces apoptosis in cancer cells.